Clinical Trials Directory

Trials / Completed

CompletedNCT04531709

Financial Toxicity and Quality of Life in Patients With TGCT

Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors

Status
Completed
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
The University of Texas Health Science Center at San Antonio · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

Conditions

Interventions

TypeNameDescription
OTHERComprehensive Score for financial toxicity (COST)Measure indirect and direct health care cost that burden patients and their loved ones.
OTHERFunctional Assessment of Cancer Therapy: General (FACT-G)General quality of life instrument
OTHEREORTC QLQ C-30Assess quality of life in cancer patients
OTHEREORTC QLQ-TC26.To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.

Timeline

Start date
2023-03-01
Primary completion
2025-02-04
Completion
2025-02-04
First posted
2020-08-28
Last updated
2025-07-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04531709. Inclusion in this directory is not an endorsement.